Repatha is a medicine containing the active ingredient(s) evolocumab. On this page you will find out more about Repatha, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: evolocumab
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Repatha 140 mg/mL injection solution, 1 mL syringe
Consumer Medicine Information leaflet:
No consumer medicine information leaflet was found for the pack size you selected. It may be unavailable or there may be a technical problem. You should speak to your pharmacist, healthcare professional, or call healthdirect on 1800 022 222 for more information.
What this medicine is for
Repatha is indicated as an adjunct to diet and exercise in: - Primary hypercholesterolaemia Repatha is indicated in adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD): - in combination with a statin or statin with other lipid lowering therapies, or - in combination with other lipid-lowering therapies in patients who are statin-intolerant. The effect of Repatha on cardiovascular morbidity and mortality has not been determined.,Homozygous familial hypercholesterolaemia Repatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid lowering therapies.
Table of characteristics
|Visual appearance||Clear to opalescent, colourless to yellowish solution|
|Dosage Form||Injection, solution|
|Route of administration||Subcutaneous|
1: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store at 2 to 8 degrees Celsius|
|Storage conditions||No information available|
|Life time||2 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.